Potent PDE5 inhibitor (IC50
= 1.23 nM). Shows >100-fold selectivity for PDE5 over PDE6. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Emerging drugs for the treatment of benign prostatic obstruction.
Hashim and Abrams
The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.
Rawson et al.